Dasatinib + Quercetin

The reviewed endpoints span biological measures, bone outcomes and gait speed. An early marker signal and a durable functional benefit are different findings.

A change in a laboratory marker, a test score and everyday function are different outcomes. A statistically detectable result does not by itself tell us whether someone would notice a worthwhile difference.

Check the measured endpoint, comparison and study population. The full profile preserves effect estimates and the source's clinical-significance assessment, including when that assessment is not supplied.

The claim to test: An early senolytic signal proves rejuvenation in humans.

What the reviewed records say:

The gap: Short-term biomarkers, small pilots and uncontrolled comparisons cannot establish broad rejuvenation or longer life.

Durability, effects in other populations and healthy-lifespan outcomes need their own evidence.

Independent replication, meaningful human outcomes, longer follow-up and better safety reporting would make these results easier to interpret.

Short-term biomarkers, small pilots and uncontrolled comparisons cannot establish broad rejuvenation or longer life.